Adults hospitalized for acute COPD exacerbation faced elevated odds for all-cause mortality and ICU admission if they had end-stage renal disease and were on dialysis, according to data presented at ...
Brensocatib, a DPP1 inhibitor, is the first FDA-approved therapy for non-cystic fibrosis bronchiectasis, showing significant clinical and structural benefits. The ASPEN trial demonstrated that ...
The findings of three retrospective studies provide valuable insights into the burden of bronchiectasis across different ...
A tool combining CV risk score (CVRS) and coronary artery calcium score (CACS) facilitates stratification of patients with COPD at risk for MACE.
Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both ...
Each year, the European Lung Foundation (ELF) recognises outstanding research that advances patient-centred care and promotes ...
Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies in 1H26 - - New Drug Application for rademikibart ...
CHICAGO — Hospital volume affected the length of stay for patients with COPD who elect to have endobronchial valve placement, with some association with costs as well, according to an abstract ...
Q3 2025 Earnings Call November 10, 2025 5:00 PM ESTCompany ParticipantsRick Winningham - CEO & DirectorRhonda Farnum ...
The researchers found that RSV vaccination was 82.3% effective in protecting against hospital admission for participants with ...
Wellbeing Whisper on MSN
Oregon PM2.5 Spike Prompts Urgent Stay-Inside Advisory
The invisible menace of fine particle pollution, in the still morning hours of southern Deschutes and northern Klamath ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback